VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Price, Quote, News and Overview
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
VX1.DE Quote, Performance and Key Statistics
FRA:VX1 (3/7/2025, 7:00:00 PM)
450.1
-1.9 (-0.42%)
The current stock price of VX1.DE is 450.1 EUR. In the past month the price decreased by -1.76%. In the past year, price increased by 18.4%.
VX1.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
| 1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
| AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
| 1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
| GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
| ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
| IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
| 1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 13.19B | ||
| 1MRNA.MI | MODERNA INC | N/A | 12.34B |
Related stock screener links
About VX1.DE
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 5,400 full-time employees. The firm is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 5400
Company Website: https://www.vrtx.com/
Investor Relations: https://investors.vrtx.com/
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of VX1.DE is 450.1 EUR. The price decreased by -0.42% in the last trading session.
What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VX1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is VX1.DE stock listed?
VX1.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?
39 analysts have analysed VX1.DE and the average price target is 489.06 EUR. This implies a price increase of 8.66% is expected in the next year compared to the current price of 450.1. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a market capitalization of 115.58B EUR. This makes VX1.DE a Large Cap stock.
How many employees does VERTEX PHARMACEUTICALS INC have?
VERTEX PHARMACEUTICALS INC (VX1.DE) currently has 5400 employees.
What are the support and resistance levels for VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a support level at 450.09 and a resistance level at 450.2. Check the full technical report for a detailed analysis of VX1.DE support and resistance levels.
Is VERTEX PHARMACEUTICALS INC (VX1.DE) expected to grow?
The Revenue of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 9.78% in the next year. Check the estimates tab for more information on the VX1.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VX1.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VX1.DE, evaluating the profitability, health, valuation and growth aspects
- VERTEX PHARMACEUTICALS INC (VX1.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Sales and EPS estimates to see what analysts future expectations are.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Chart to make your own analysis
- VERTEX PHARMACEUTICALS INC (VX1.DE) Latest news and press-releases to stay up to date.
Does VERTEX PHARMACEUTICALS INC (VX1.DE) stock pay dividends?
VX1.DE does not pay a dividend.
When does VERTEX PHARMACEUTICALS INC (VX1.DE) report earnings?
VERTEX PHARMACEUTICALS INC (VX1.DE) will report earnings on 2025-05-05, after the market close.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (VX1.DE)?
The PE ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 1667.04. This is based on the reported non-GAAP earnings per share of 0.27 and the current share price of 450.1 EUR. Check the full fundamental report for a full analysis of the valuation metrics for VX1.DE.
VX1.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VX1.DE. When comparing the yearly performance of all stocks, VX1.DE is one of the better performing stocks in the market, outperforming 78.68% of all stocks.
VX1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE. While VX1.DE has a great health rating, its profitability is only average at the moment.
VX1.DE Financial Highlights
Over the last trailing twelve months VX1.DE reported a non-GAAP Earnings per Share(EPS) of 0.27. The EPS decreased by -98.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.38% | ||
| ROE | -3.26% | ||
| Debt/Equity | 0.01 |
VX1.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VX1.DE. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 6237.42% and a revenue growth 9.78% for VX1.DE